Disappointment as Alzheimer’s drug flops
Widely anticipated results from a major Alzheimer’s trial have dashed hopes that a disease-modifying treatment may be around the corner.
Eli Lilly has announced that its anti-amyloid agent solanezumab failed to slow cognitive decline in people with mild dementia in a phase 3 trial.
The monoclonal antibody was trialled in 2100 patients diagnosed with early Alzheimer’s disease. The randomised trial was placebo-controlled for 18 months